FINWIRES · TerminalLIVE
FINWIRES

$AZN

81 stories mentioning AZNUpdated 2d ago

Every FINWIRES story that references AZN, newest first.

What are analysts saying about AZN?

Recent broker actions mentioned in FINWIRES coverage. Compiled from wire headlines; not investment advice.

What's the latest news on AZN?

Wire

AstraZeneca Says Late-Stage Etcamah Breast-Cancer Trial Misses Main Goal

AstraZeneca (AZN) said Friday its late-stage trial testing Etcamah with palbociclib, a widely used breast-cancer therapy, did not meet its primary goal of improving progression-free survival.The company said it observed a numerical improvement in first-line treatment of patients with estrogen receptor-positive, HER2-negative advanced breast cancer who had not received any systemic treatment for advanced disease.The trial compared Etcamah plus palbociclib with an aromatase inhibitor plus palbociclib, AstraZeneca said.The safety profile of Etcamah in combination with palbociclib was consistent with the known safety profile of each medicine, the company said.AstraZeneca shares fell 3.3% in after-hours trading.

$AZN
Asia Markets

European Equities Traded in the US as American Depositary Receipts Drop in Thursday Trading

European equities traded in the US as American depositary receipts were trending lower late Thursday morning, declining 0.41% to 1,938.57 on the S&P Europe Select ADR Index.From continental Europe, the gainers were led by biopharmaceutical company Cellectis (CLLS) and accommodations booking site trivago (TRVG), which advanced 1.6% and 1.1% respectively. They were followed by medical device maker EDAP TMS (FOCL) and 3D printer company Materialise (MTLS), which increased 1.2% and 0.8% respectively.The decliners from continental Europe were led by biotech firm Evaxion (EVAX) and biopharmaceutical company DBV Technologies (DBVT), which lost 5% and 2.7% respectively. They were followed by biotech firm BioNTech (BNTX) and biopharmaceutical company Grifols (GRFS), which were down 1.8% and 1.7% respectively.The gainers from the UK were led by software firm Endava (DAVA) and biopharmaceutical company Akari Therapeutics (AKTX), which were up 2% and 1.6% respectively. They were followed by telecommunications operator Vodafone Group (VOD) and pharmaceutical company AstraZeneca (AZN), which rose 1.2% and 1.5% respectively.The decliners from the UK and Ireland were led by mining company BHP Group (BHP) and biotech firm Trinity Biotech (TRIB), which fell 4.7% and 5.6% respectively. They were followed by biopharmaceutical companies Amarin (AMRN) and Biodexa Pharmaceuticals (BDRX), which dropped 2.2% and 3% respectively.

$AKTX$AMRN$AZN$BDRX$BHP$BNTX$CLLS$DAVA$DBVT$EVAX$FOCL$GRFS$MTLS$TRIB$TRVG$VOD
Research

RBC Initiates AstraZeneca at Outperform With GBP145 Price Target

AstraZeneca's (AZN) London stock has an average rating of buy and mean price target of GBP160.21, according to analysts polled by FactSet.

$AZN
Wire

Top Midday Stories: GE Aerospace to Acquire Consolidated Precision Products; Qualcomm Issues Share Warrant to Amazon

All three major US stock indexes fell in late-morning trading Tuesday as oil prices climbed and investors monitored developments in the US-Iran war and US trade negotiations with Canada.In company news, GE Aerospace (GE) agreed to acquire Consolidated Precision Products from Warburg Pincus and Berkshire Partners for $11.75 billion. GE shares rose 0.5% around midday.Qualcomm (QCOM) issued a warrant to an Amazon.com (AMZN) affiliate last week to acquire up to 25 million shares at $161.26 each, the chipmaker said. Qualcomm is also collaborating with Amazon to produce customized silicon for large-scale AI data centers and optical connectivity products. Qualcomm shares rose 4.6%, and Amazon fell 0.5%.Novartis (NVS) said its phase 3 Harbor study evaluating delpacibart etedesiran in patients with myotonic dystrophy type 1 failed to meet its primary endpoint of video hand opening time. Separately, Monte Rosa Therapeutics (GLUE) will receive a $50 million milestone payment from Novartis after initiating a phase 2 clinical trial of MRT-6160 to treat Sjogren's disease. Novartis shares slumped 13%, and Monte Rosa rose 1.7%.Boston Scientific (BSX) identified a cybersecurity incident affecting certain information technology systems that resulted in a global disruption of its operations. The company expects to recover part of the affected revenue but said it is unlikely to meet its net sales growth and adjusted EPS guidance ranges for Q3 and the full year. Boston Scientific shares fell 4.6%.Meta Platforms (META) has run over 300 paid advertisements allegedly containing child sexual abuse material this year, according to an investigation by the Tech Transparency Project, a nonprofit watchdog organization. Hours after TTP shared its findings with the company, Meta removed about 150 of the ads that were still visible in its database of advertising that has run on its platforms, the group said. Meta shares were little changed.Amgen (AMGN) said its phase 3 DeLLphi-305 study met its primary endpoint with Imdelltra in combination with AstraZeneca's (AZN) Imfinzi, showing a statistically significant and clinically meaningful improvement in overall survival in patients with extensive-stage small cell lung cancer. Amgen shares still fell 9.6%, and AstraZeneca dropped 0.9%.Price: $338.76, Change: $+1.63, Percent Change: +0.48%

$AMGN$AMZN$AZN$BSX$GE$GLUE$META$NVS$QCOM
Wire

Amgen Says Phase 3 Study Meets Primary Endpoint in Small Cell Lung Cancer

Amgen (AMGN) said Tuesday its phase 3 DeLLphi-305 study met its primary endpoint, with Imdelltra in combination with AstraZeneca's (AZN) Imfinzi showing a statistically significant and clinically meaningful improvement in overall survival in patients with extensive-stage small cell lung cancer.The study evaluated the combination as first-line maintenance treatment for patients with extensive-stage small cell lung cancer whose disease had not progressed after initial treatment, Amgen said. The combination also improved progression-free survival and objective response rate, the company said.The safety profile was consistent with the known profiles of the individual medicines, with no new or unexpected safety signals identified, the company said, adding that it plans to present detailed results at an upcoming medical congress and share the data with regulatory authorities.Price: $402.00, Change: $-35.23, Percent Change: -8.06%

$AMGN$AZN
Asia Markets

European Equities Traded in the US as American Depositary Receipts Head Lower in Tuesday Trading

European equities traded in the US as American depositary receipts were trending lower in late Tuesday morning trading, declining 0.50% to 1,960.50 on the S&P Europe Select ADR Index.From continental Europe, the gainers were led by software firm SAP (SAP) and pharmaceutical company Sanofi (SNY), which increased 1.7% and 1.6% respectively. They were followed by healthcare tech company Royal Philips (PHG) and biopharmaceutical company DBV Technologies (DBVT), which were up 1.5% and 1.3% respectively.The decliners from continental Europe were led by telecommunications company Nokia (NOK) and biopharmaceutical company Cellectis (CLLS), which lost 3.8% and 2.9% respectively. They were followed by biotech firm Evaxion (EVAX) and furniture maker Natuzzi (NTZ), which dropped 1.6% and 1.5% respectively.The gainers from the UK were led by software firm Endava (DAVA) and communications company WPP (WPP), which advanced 4.1% and 2.6% respectively. They were followed by pharmaceutical company AstraZeneca (AZN) and biotech company Trinity Biotech (TRIB), which rose 1.8% and 1.4% respectively.The decliners from the UK and Ireland were led by biopharmaceutical company Mereo BioPharma Group (MREO) and pharmaceutical company Silence Therapeutics (SLN), which fell 2.5% and 2.4% respectively. They were followed by biopharmaceutical company Akari Therapeutics (AKTX) and lender Barclays (BCS), which were down 2.2% and 1.7% respectively.

$AKTX$AZN$BCS$CLLS$DAVA$DBVT$EVAX$MREO$NOK$NTZ$PHG$SAP$SLN$SNY$TRIB$WPP
Sectors

Sector Update: Healthcare Stocks Rise Late Afternoon

Healthcare stocks were higher late Wednesday afternoon, with the NYSE Healthcare Index and the State Street Health Care Select Sector SPDR ETF (XLV) each adding 1.2%.The iShares Biotechnology ETF (IBB) increased 0.5%.In corporate news, Eli Lilly (LLY) shares rose 4.7% after it posted higher Q2 non-GAAP earnings and revenue in addition to raising its 2026 sales guidance. Separately, CVS Health (CVS) said Wednesday it revamped its direct-to-consumer weight management program, lowering the cost of virtual visits and expanding access to GLP-1 medications through a collaboration with Lilly. CVS shares were down 3.8%.Novo Nordisk (NVO) said Wednesday it won a preliminary injunction in the Netherlands against Ceban Ziekenhuisfarmacie in a patent-infringement case involving its compounded semaglutide nasal spray. Novo shares added 0.6%.AstraZeneca (AZN) and Bristol Myers Squibb (BMY) are not engaged in discussions over a potential merger, Reuters reported Wednesday, citing a senior source close to the matter. AstraZeneca shares rose 3.5%, and Bristol Myers Squibb fell 3.2%.Charles River Laboratories (CRL) on Wednesday reported fiscal Q2 non-GAAP earnings and sales above market expectations and raised its 2026 non-GAAP EPS guidance. Its shares jumped 11%.

$AZN$BMY$CRL$CVS$LLY$NVO
Sectors

Sector Update: Healthcare Stocks Advance Wednesday Afternoon

Healthcare stocks were higher Wednesday afternoon, with the NYSE Healthcare Index rising 1.1% and the State Street Health Care Select Sector SPDR ETF (XLV) adding 1%.The iShares Biotechnology ETF (IBB) increased 0.9%.In corporate news, Eli Lilly (LLY) shares rose 3.7% after it posted higher Q2 non-GAAP earnings and revenue in addition to raising its 2026 sales guidance. Separately, CVS Health (CVS) said Wednesday it revamped its direct-to-consumer weight management program, lowering the cost of virtual visits and expanding access to GLP-1 medications through a collaboration with Lilly. CVS shares were down 4.9%.Novo Nordisk (NVO) said Wednesday it won a preliminary injunction in the Netherlands against Ceban Ziekenhuisfarmacie in a patent-infringement case involving its compounded semaglutide nasal spray. Novo shares rose 1.3%.AstraZeneca (AZN) and Bristol Myers Squibb (BMY) are not engaged in discussions over a potential merger, Reuters reported Wednesday, citing a senior source close to the matter. AstraZeneca shares rose nearly 4%, and Bristol Myers Squibb fell 3.5%.

$AZN$BMY$CVS$LLY$NVO
Wire

Update: Market Chatter: AstraZeneca, Bristol Myers Not Pursuing Merger Talks

(Updates with responses from the companies in the third paragraph.)AstraZeneca (AZN) and Bristol Myers Squibb (BMY) are not engaged in discussions over a potential merger, Reuters reported Wednesday, citing a senior source close to the matter."There is no deal between AstraZeneca and BMS. There never was a deal to be done, and there are no discussions between the companies," the source told Reuters.AstraZeneca and Bristol Myers Squibb declined to comment on the matter.(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)Price: $162.62, Change: $+7.00, Percent Change: +4.50%

$AZN$BMY
Asia Markets

European Equities Traded in the US as American Depositary Receipts Edge Up in Wednesday Trading

European equities traded in the US as American depositary receipts were edging higher late Wednesday morning, up 0.2% to 1,940.47 on the S&P Europe Select ADR Index.From continental Europe, the gainers were led by biopharmaceutical company DBV Technologies (DBVT) and semiconductor firm Sequans Communications (SQNS), which rose 3.6% and 3.3% respectively. They were followed by argenx (ARGX) and Novo Nordisk (NVO), which rose 3.2% and 2.8% respectively.The decliners from continental Europe were led by internet ad firm Criteo (CRTO) and biopharmaceutical company Cellectis (CLLS), which dropped 18% and 1.8% respectively. They were followed by telecommunications company Nokia (NOK) and biopharmaceutical company Grifols (GRFS), which were down 1.5% and 1.3% respectively.The gainers from the UK were led by pharmaceutical company AstraZeneca (AZN) and communications company WPP (WPP), which increased 4.6% and 3.4% respectively. They were followed by educational publisher Pearson (PSO) and hospitality company Intercontinental Hotels Group (IHG), which were up 2.5% and 2.1% respectively.The decliners from the UK and Ireland were led by Biodexa Pharmaceuticals (BDRX) and insurance company Prudential (PUK), which fell 8.1% and 4.7% respectively. They were followed by Akari Therapeutics (AKTX) and lender HSBC (HSBC), which lost 3.6% and 3.2% respectively.

$AKTX$ARGX$AZN$BDRX$CLLS$CRTO$DBVT$GRFS$HSBC$IHG$NOK$NVO$PSO$PUK$SQNS$WPP
Wire

Bristol Myers Squibb Potential Deal With AstraZeneca Seen Unlikely as Shareholder Views Diverge, RBC Says

Bristol Myers Squibb's (BMY) reported merger discussions with AstraZeneca (AZN) will unlikely result in a transaction as AstraZeneca's shareholders could broadly oppose the combination, RBC Capital Markets said in a Tuesday note.According to the note, investors generally viewed the talks as credible following the companies' silence after the media report, but most considered the probability of a deal to be low.AstraZeneca shareholders questioned the rationale for the transaction and expressed concerns about growth, while several viewed the report as a trial balloon that could ultimately be abandoned, the analysts said.RBC also said Bristol Myers investors were generally constructive toward a transaction but the support depended ona substantial premium and clear value creation. Investors indicated a 40% to 50% premium could be needed to meet return thresholds, while upcoming data for Milvexian and Cobenfy could strengthen Bristol Myers' standalone position and negotiating leverage.RBC maintained its sector perform rating and $64 price target on Bristol Myers Squibb.Price: $64.48, Change: $-0.99, Percent Change: -1.51%

$AZN$BMY
Wire

AstraZeneca Collaborates With Sophia Genetics on Companion Diagnostics for Oncology Therapies

AstraZeneca (AZN) has entered into a multi-year global collaboration with Sophia Genetics (SOPH) aiming to advance the development and commercialization of two companion diagnostic programs supporting precision oncology therapies, Sophia Genetics said Tuesday.The collaboration will bring Sophia Genetics' decentralized clinical trial assays and companion diagnostic capabilities to AstraZeneca therapies, according to a statement.Financial terms of the collaboration were not provided.Price: $157.64, Change: $-0.33, Percent Change: -0.21%

$AZN$SOPH
Sectors

Sector Update: Healthcare Stocks Softer Late Afternoon

Healthcare stocks declined late Monday afternoon, with the NYSE Healthcare Index falling 0.7% and the State Street Health Care Select Sector SPDR ETF (XLV) down 0.1%.The iShares Biotechnology ETF (IBB) shed 0.2%.In corporate news, Integer (ITGR) agreed to be acquired and taken private by investment firm KKR (KKR) in an all-cash deal with an enterprise value of about $5.7 billion. Integer shares rose 2.6%.AstraZeneca (AZN) is in talks with Bristol Myers Squibb (BMY) about a potential combination that would create a company valued at almost $400 billion, the Financial Times reported Sunday. AstraZeneca shares slumped 6.8%, and Bristol Myers rose 0.4%.Lantheus Holdings (LNTH) agreed to be acquired and taken private by Curium for up to $8 billion. Lantheus shares rose 1.7%.Krystal Biotech (KRYS) shares dropped 8.4% after its Q2 product revenue fell short of analysts' estimates.

$AZN$BMY$ITGR$KRYS$LNTH
Asia Markets

Update: US Equity Indexes Rise Amid Rally in Communication Services; Crude Oil Slides With Treasury Yields

US equity indexes rose after midday Monday amid strong gains in communications services, while a slide in government bond yields accompanied a drop in crude oil futures.The Nasdaq Composite jumped 2.2% to 25,923.9, with the S&P 500 up 1.4% to 7,596.8 and the Dow Jones Industrial Average higher by 1.1% to 53,071.2.Communication services surged 4.5%, topping sector charts, followed by a rise in consumer discretionary and technology. Energy, healthcare and consumer staples led decliners."Iranian Leadership is unbelievably duplicitous!" President Donald Trump said in a social media post Monday, reverting to lashing out at Iran after canceling a planned attack against the Islamic Republic last Saturday because the "perimeters of a deal has been agreed to.""Nothing gets through to Iran unless we want it to, and nothing will get through unless a Deal, or Total Surrender, is accomplished," the US president said, referring to the US blockade of Iranian ports. "Whether Iran wants to admit it or not, we are, in fact, talking of a solution to a problem that they have caused, for decades."Iran's Foreign Ministry Spokesman Esmaeil Baghaei said no negotiations with the US were underway and no meetings were scheduled, Reuters reported.Oman and Iran have been negotiating over a new maritime route through the Strait of Hormuz, which borders both their territorial waters, Al Jazeera, a Middle Eastern broadcaster, reported. Sunday night, Iran's Foreign Minister Abbas Araghchi told the Iranian cabinet in a report that negotiations between Tehran and Muscat were "on the way to being finalized".The front-month US West Texas Intermediate crude oil slumped 5.4% to $80.08 a barrel, and global benchmark North Sea Brent dropped 4.9% to $83.66 a barrel.Most US Treasury yields declined, with the 10-year trading down 5.5 basis points to 4.69%, retreating from the 52-week high touched late last week. The two-year yield dropped 3.1 basis points to 4.26%.In precious metal markets, gold futures slipped 0.4% to $4,090.5, while silver futures were unchanged at $57.77.In economic news, the Institute for Supply Management's US manufacturing index rose to 55.6 in July from 53.3 in June, compared with expectations for 53.9 in a Bloomberg-compiled survey. This is the highest reading since May 2022, ISM said.The S&P Global US manufacturing index for July was revised upward to 53.9 from the flash reading of 53.8, compared with expectations for no revision in a survey compiled by Bloomberg.In company news, Alibaba (BABA) launched Qwen3.8-Max, its latest large language model, and plans to release the model's open weights next week alongside Qwen3.8-27B.Bristol Myers Squibb (BMY) is in talks with AstraZeneca (AZN) about a potential combination that would create a pharmaceutical company valued at nearly $400 billion, the Financial Times reported.Marriott International (MAR) reported Q2 revenue below estimates amid headwinds from the Middle East conflict, and offered a downbeat Q3 earnings outlook. Shares slumped 6.3%, among the worst performers on the Nasdaq and the S&P 500.

Dow JonesNasdaq CompositeS&P 500$AZN$BABA$BMY$MAR
Sectors

Sector Update: Healthcare Stocks Decline Monday Afternoon

Healthcare stocks declined Monday afternoon, with the NYSE Healthcare Index falling 1% and the State Street Health Care Select Sector SPDR ETF (XLV) dropping 0.5%.The iShares Biotechnology ETF (IBB) shed 0.7%.In corporate news, Integer (ITGR) agreed to be acquired and taken private by investment firm KKR (KKR) in an all-cash deal with an enterprise value of about $5.7 billion. Integer shares rose 2.7%.AstraZeneca (AZN) is in talks with Bristol Myers Squibb (BMY) about a potential combination that would create a company valued at almost $400 billion, the Financial Times reported Sunday. AstraZeneca shares slumped 7.5%, and Bristol Myers dropped 0.8%.Lantheus Holdings (LNTH) agreed to be acquired and taken private by Curium for up to $8 billion. Lantheus shares rose 2.2%.

$AZN$BMY$ITGR$LNTH
Wire

Top Midday Stories: Amazon Market Cap Hits $3 Trillion; AstraZeneca, Bristol Myers Squibb Reportedly Discuss $400 Billion Combination

All three major US stock indexes were up in late-morning trading Monday after President Donald Trump said Sunday he cancelled a planned attack on Iran.In company news, Amazon.com (AMZN) shares rose Monday morning, bringing the tech giant's market capitalization above $3 trillion for the first time. Amazon shares were up 5.2% around midday.AstraZeneca (AZN) is in talks with Bristol Myers Squibb (BMY) about a potential combination that would create a company valued at nearly $400 billion, the Financial Times reported Sunday, citing people familiar with the matter. The companies have held discussions in recent months, though a deal could still be delayed or fail to materialize, the report said, citing the people. AstraZeneca shares were down 9.4%, while Bristol Myers Squibb shares were down 0.7%.Lantheus (LNTH) said Monday it signed a definitive agreement to merge with a unit of Curium US Holdings in a deal valued at up to $8 billion. The buyer will pay $102.50 per Lantheus share in cash at closing and up to $12 per share in future milestone-based cash payments through 2030, the company said. The deal is expected to close in H1 2027, subject to regulatory and shareholder approvals. Lantheus shares were up 2.8%.Visa (V) said Monday it has agreed to acquire fraud intelligence company BioCatch for $2.4 billion in cash. The deal will likely close by the end of Visa's fiscal Q2 2027, the company said. Visa shares were up 0.1%.ArcelorMittal (MT) said Monday it has expanded its partnership with Microsoft (MSFT) to implement artificial intelligence tools in its international business processes. The mining company will adopt Microsoft Azure as its primary cloud infrastructure to update core information technology frameworks and centralize data, it said. ArcelorMittal shares were up 1.4%, while Microsoft shares were up 4.9%.JPMorgan Chase (JPM) said Monday it plans to spend $750 billion through 2035 to increase the housing supply and support home ownership in the US. JPMorgan shares were up 0.2%.GameStop (GME) has agreed to exchange about $1.4 billion of its outstanding 0% convertible senior notes due 2030 and 2032 for its class A common stock without the use of cash. Noteholders are exchanging around $400 million of the 2030 notes and $1 billion of the 2032 notes, the company said. The exchange is expected to close around Sept. 23. GameStop shares were down 12.6%.Price: $285.78, Change: $+14.20, Percent Change: +5.23%

$AMZN$AZN$BMY$GME$JPM$LNTH$MSFT$MT$V
Asia Markets

European Equities Traded in the US as American Depositary Receipts Decline in Monday Trading

European equities traded in the US as American depositary receipts started the week off lower late Monday morning, declining 0.35% to 1,925.58 on the S&P Europe Select ADR Index.From continental Europe, the gainers were led by accommodations booking site trivago (TRVG) and software firm SAP (SAP), which rose 4% and 3.3%, respectively. They were followed by telecommunications company Ericsson (ERIC) and 3D printer company Materialise (MTLS), which were up 2.5% and 2.4%, respectively.The decliners from continental Europe were led by petroleum refiner Equinor (EQNR) and brewing company Anheuser-Busch InBev (BUD), which dropped 2.8% and 2.4%, respectively. They were followed by oil and gas company Eni (E) and biopharmaceutical company argenx (ARGX), which were down 2.2% and 1.9%, respectively.The gainers from the UK were led by biotech firm Autolus Therapeutics (AUTL) and biopharmaceutical company Biodexa Pharmaceuticals (BDRX), which advanced 30% and 6.8%, respectively. They were followed by pharmaceutical company Silence Therapeutics (SLN) and biopharmaceutical company NuCana (NCNA), which increased 5.9% and 3%, respectively.The decliners from the UK and Ireland were led by pharmaceutical company AstraZeneca (AZN) and biotech firm Trinity Biotech (TRIB), which fell 8.1% and 2.9%, respectively. They were followed by oil and gas company BP (BP) and biopharmaceutical company Akari Therapeutics (AKTX), which lost 2.3% and 2.1%, respectively.

$AKTX$ARGX$AUTL$AZN$BDRX$BP$BUD$E$EQNR$ERIC$MTLS$NCNA$SAP$SLN$TRIB$TRVG
Sectors

Sector Update: Healthcare Stocks Rise Pre-Bell Monday

Healthcare stocks were rising pre-bell Monday, with the State Street Health Care Select Sector SPDR ETF (XLV) 1.2% higher and the iShares Biotechnology ETF (IBB) advancing by 0.8%.AstraZeneca (AZN) is in talks with Bristol Myers Squibb (BMY) about a potential combination that would create a pharmaceutical company valued at nearly $400 billion, the Financial Times reported, citing unnamed people familiar with the matter. Astrazeneca stock was 7% lower, while Bristol Myers Squibb shares were up more than 3% premarket.Supernus Pharmaceuticals (SUPN) and Indivior Pharmaceuticals (INDV) said they will merge in a tax-free, all-stock deal. Shares of Supernus Pharmaceuticals were up more than 14% and Indivior Pharmaceuticals stock advanced past 1% pre-bell.KKR (KKR) entered into a definitive agreement to acquire Integer (ITGR) through affiliated funds in an all-cash transaction at an enterprise value of $5.7 billion, the companies said. Integer shares were up more than 2% premarket.

$AZN$BMY$IBB$INDV$ITGR$KKR$SUPN$XLV
Asia Markets

Exchange-Traded Funds, Equity Futures Higher Pre-Bell Monday Amid US-Iran Truce Hopes

The broad market exchange-traded fund SPDR S&P 500 ETF Trust (SPY) was up 0.5%, and the actively traded Invesco QQQ Trust (QQQ) was 0.2% higher in Monday's premarket activity as traders hope for a US-Iran truce.US stock futures were higher, with S&P 500 Index futures up 0.5%, Dow Jones Industrial Average futures advancing 0.9%, and Nasdaq futures gaining 0.3% before the start of regular trading.July's manufacturing data from S&P Global will be released at 9:45 am ET.The ISM's manufacturing report and June's construction data will be released at 10 am ET.In premarket activity, bitcoin was down by 1.4%. Among cryptocurrency ETFs, the cryptocurrency fund ProShares Bitcoin Strategy ETF (BITO) was 0.8% lower, Ether ETF (EETH) retreated 1.7%, and Bitcoin & Ether Market Cap Weight ETF (BETH) declined 0.1%.Power Play:ConsumerThe State Street Consumer Staples Select Sector SPDR ETF (XLP) was up 0.8%, the Vanguard Consumer Staples Index Fund ETF Shares (VDC) was down 0.2%, and the iShares US Consumer Staples ETF (IYK) was 0.9% lower. The State Street Consumer Discretionary Select Sector SPDR ETF (XLY) increased 1.1%. The VanEck Retail ETF (RTH) and the State Street SPDR S&P Retail ETF (XRT) were inactive.Alibaba (BABA) shares were up more than 4% pre-bell after the company said in a social media post that it launched Qwen3.8-Max, its latest large language model, and plans to release the model's open weights next week alongside Qwen3.8-27B.Winners and Losers:Health CareThe State Street Health Care Select Sector SPDR ETF (XLV) advanced 1.1%, the Vanguard Health Care Index Fund (VHT) was up 0.8%, while the iShares US Healthcare ETF (IYH) increased 0.04%. The iShares Biotechnology ETF (IBB) was 0.4% higher.AstraZeneca (AZN) stock was down more than 4% premarket, while Bristol Myers Squibb (BMY) gained 4% after Financial Times reported Sunday that the companies are in talks about a potential combination that would create a pharmaceutical company valued at nearly $400 billion.TechnologyThe State Street Technology Select Sector SPDR ETF (XLK) retreated 0.5%, the iShares US Technology ETF (IYW) was flat, and the iShares Expanded Tech Sector ETF (IGM) was up 0.1%. Among semiconductor ETFs, the State Street SPDR S&P Semiconductor ETF (XSD) was 1.5% lower, while the iShares Semiconductor ETF (SOXX) fell by 2.4%.Parsons (PSN) shares were up more than 2% in premarket activity after the company said it will serve as the lead designer for the Interstate 526 Long Point Road Interchange Improvements project in South Carolina.FinancialThe State Street Financial Select Sector SPDR ETF (XLF) advanced 0.8%. Direxion Daily Financial Bull 3X Shares (FAS) was up 2.3%, while its bearish counterpart, Direxion Daily Financial Bear 3X Shares (FAZ), was 2.3% lower.KKR (KKR) shares were up more than 1% in early hours activity after the company entered into a definitive agreement to acquire Integer (ITGR) through affiliated funds in an all-cash transaction at an enterprise value of $5.70 billion. Integer stock was 2.6% higher.IndustrialThe State Street Industrial Select Sector SPDR ETF (XLI) advanced 0.6%, while the Vanguard Industrials Index Fund (VIS) was up 0.6% and the iShares US Industrials ETF (IYJ) was 0.4% higher.Boeing (BA) stock was up more than 1% before the opening bell after the company said it has delivered Somon Air's first 737 Max aircraft.EnergyThe iShares US Energy ETF (IYE) was inactive, while the State Street Energy Select Sector SPDR ETF (XLE) was down by 1.2%.Shell (SHEL) stock was down more than 1% before market open after the company agreed to sell its European onshore renewables portfolio to TotalEnergies (TTE). TotalEnergies' shares were 0.6% lower.CommoditiesFront-month US West Texas Intermediate crude oil fell by 6.8% to $78.92 per barrel on the New York Mercantile Exchange. Natural gas was up 0.8% at $2.77 per 1 million British Thermal Units. The United States Oil Fund (USO) decreased by 6.8%, while the United States Natural Gas Fund (UNG) was 0.5% higher.Gold futures for November advanced by 0.2% to $4,114.80 an ounce on the Comex. Silver futures gained by 0.7% to reach $58.18 an ounce. SPDR Gold Shares (GLD) was up by 0.1%, and the iShares Silver Trust (SLV) fell by 0.4%.

Dow JonesNasdaq CompositeS&P 500$AZN$BA$BABA$BETH$BITO$BMY$EEM$EETH$EXI$FAS$FAZ$GLD$IBB$IGM$IGV$IPK$ITGR$IVV$IWM$IYE$IYH$IYJ$IYK$IYW$KKR$PMR$PSN$QQQ$RTH$SHEL$SLV$SOXX$SPY$TTE$UNG$USO$VDC$VHT$VIS$XLE$XLF$XLI$XLK$XLP$XLV$XLY$XRT$XSD
Sectors

Sector Update: Healthcare

Healthcare stocks were rising pre-bell Monday, with the State Street Health Care Select Sector SPDR ETF (XLV) 1.2% higher and the iShares Biotechnology ETF (IBB) advancing by 0.5%.AstraZeneca (AZN) is in talks with Bristol Myers Squibb (BMY) about a potential combination that would create a pharmaceutical company valued at nearly $400 billion, the Financial Times reported, citing unnamed people familiar with the matter. Astrazeneca stock was 7% lower, while Bristol Myers Squibb shares were up more than 4% premarket.

$AZN$BMY

Showing 1-20 of 81

Track with the FINWIRES app suite

FolioX
FolioX
Track AZN in your portfolio
WheelAI
WheelAI
Analyze AZN options with the wheel strategy
StockInsider
StockInsider
See market sentiment on AZN